argenx SE (ARGX)

Market Cap	51.30B +32.7%
Revenue (ttm)	4.25B +89.0%
Net Income	1.29B +55.1%
EPS	19.57 +53.1%
Shares Out	61.73M
PE Ratio	39.71
Forward PE	24.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	434,107
Open	838.28
Previous Close	840.28
Day's Range	815.83 - 848.83
52-Week Range	510.06 - 934.62
Beta	-0.17
Analysts	Strong Buy
Price Target	979.22 (+19.86%)
Earnings Date	Feb 26, 2026

About ARGX

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 18, 2017
• Employees: 1,599
• Stock Exchange: NASDAQ
• Ticker Symbol: ARGX
• Website: https://argenx.com

Financial Performance

In 2025, argenx SE's revenue was $4.25 billion, an increase of 88.95% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.

Analyst Summary

According to 19 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price target is $979.22, which is an increase of 19.86% from the latest price.

Price Target

$979.22

(19.86% upside)

Analyst Consensus: Strong Buy